Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluation of Heart Failure Treatment Guided by NTproBNP vs Clinical Symptoms and Signs Alone
This study has been completed.
Study NCT00391846 Information provided by AstraZeneca
First Received: October 19, 2006 Last Updated: March 4, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Heart Failure
Ventricular Dysfunction, Left
Additional conditions recognized in this trial
Signs and Symptoms
Ventricular Dysfunction
More general conditions related to this trial
Cardiovascular Diseases
Heart Diseases
Interventions listed in this trial
Captopril
Enalapril
Lisinopril
Ramipril
Trandolapril
Bisoprolol
Carvedilol
Metoprolol succinate
Candesartan
Valsartan
Eplerenone
Spironolactone
Diuretics
Blood samples
KCCQ Questionnaire
Additional drug interventions recognized in this trial
Metoprolol
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic beta-Antagonists
Aldosterone Antagonists
Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Anti-Arrhythmia Agents
Antihypertensive Agents
Autonomic Agents
Cardiotonic Agents
Cardiovascular Agents
Enzyme Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Protective Agents
Sympatholytics
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
AstraZeneca
Back to top of Main Content
